GC-012F is a gene-modified cell therapy commercialized by Gracell Biotechnologies, with a leading Phase II program in Relapsed Multiple Myeloma. According to Globaldata, it is involved in 12 clinical trials, of which 9 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of GC-012F’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GC-012F is expected to reach an annual total of $52 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GC0-12 is under development for the treatment of advanced relapsed/refractory multiple myeloma, newly diagnosed multiple myeloma, B-cell non-Hodgkin's lymphoma, primary mediastinal b-cell lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma and systemic lupus erythematosus. The therapy constitutes of genetically manipulated T cells which express dual chimeric antigen receptor targeting tumor cells expressing B-cell maturation antigen (BCMA) and CD19 chimeric antigen receptors. It is developed based on FasTCAR platform. It is administered through intravenous route.
Gracell Biotechnologies Overview
Gracell Biotechnology Shanghai Co Ltd operates as a biopharmaceutical company. The Company develops cellular therapeutics and other biotechnology. The company is headquartered in China.
The operating loss of the company was CNY624.7 million in FY2022, compared to an operating loss of CNY463.6 million in FY2021. The net loss of the company was CNY607.5 million in FY2022, compared to a net loss of CNY451.8 million in FY2021.
For a complete picture of GC-012F’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.